Pharmacology and Analytical Facility - HPLC and Mass Spectrometry Facility This facility provides access to sophisticated HPLC, ultra high performance liquid chromatographic and mass spectrometry instruments. In this facility, analytical assay methodologies can be developed and validated using UPLC/HPLC equipment with a broad array of quantitative detection systems (e.g. UV, photodiode array, fluorescence, radiometric, light scattering, electrochemical). Current mass spectrometry instruments include a simple single quad LC/MS instrument for use in molecular weight determinations as well as more complex tandem mass spectrometers (7 total), including a time-of-flight instrument for more intricate drug metabolism studies and experiments requiring accurate mass weight measurements. In addition, a GC/MS instrument is available for separation and quantitation of volatile compounds. Recently added were automated solid phase and liquid extraction platforms capable of isolating multiple analytes of interest (drugs, macromolecules, and protein drug targets) from complex biomatrices (blood, plasma, normal organ tissues, and tumors). These extraction systems have improved both extraction efficiency and throughput in analytical sample preparation. The laboratory has supported experiments in chemical synthesis, drug library screening, medicinal chemistry, drug discovery and development, drug metabolism, drug target identification, drug metabolism, drug tissue biodistribution, systemic pharmacokinetics, drug production solubility and stability, formulation, and tumor biochemistry. The HPLC/Mass Spectrometry Facility sampled analysis increased over 340% since 1999 and is now analyzing more than 33,000 samples per year serving over 52 faculty members who are members of 21 CCSG Programs;90% of the users have peer-reviewed funding. The current source of funding is 48.4% CCSG, and 51.6% user fees. This state of the art facility is located at a newly renovated El Rio campus located approximately 1 mile from the main campus. This location is a 7250 sq. ft. facility that houses 4 faculty members and 21 support staff as well as 25 full UPLC/HPLC systems. In addition to the advanced analytical facility the combined program faculty have in excess of 60 years of experience in analytical chemistry, analytical method development and validation, isolation technologies, pharmacology, drug metabolism, and pharmacokinetic/pharmacodynamics. They act as an invaluable resource in experimental design, development and implementation to the user faculty who often lack the specific training to conduct experiments requiring quantitative analytical chemistry and pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310856
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$448,337
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477
Liao, Zhongxing; Lee, J Jack; Komaki, Ritsuko et al. (2018) Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36:1813-1822
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113
Zhu, Hongxiao; Caspers, Philip; Morris, Jeffrey S et al. (2018) A Unified Analysis of Structured Sonar-terrain Data using Bayesian Functional Mixed Models. Technometrics 60:112-123
Li, Jialu; Fu, Chunxiao; Speed, Terence P et al. (2018) Accurate RNA Sequencing From Formalin-Fixed Cancer Tissue To Represent High-Quality Transcriptome From Frozen Tissue. JCO Precis Oncol 2018:

Showing the most recent 10 out of 12418 publications